Procore signs multi-year strategic collaboration agreement with AWS
FOSTER CITY, CA—Jolanda Howe, Senior Vice President and Global Controller at Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a biopharmaceutical company with a market capitalization of $2.18 billion and impressive revenue growth of 81% over the last twelve months, recently executed several significant stock transactions, according to a Form 4 filing with the Securities and Exchange Commission. According to InvestingPro analysis, the company maintains a strong financial health score and is currently trading near its Fair Value. On March 17, Howe sold a substantial portion of her holdings, totaling $2,426,541, with sale prices ranging from $44.3341 to $44.7481 per share.
In addition to the sales, Howe also exercised stock options, acquiring shares at a cost of $2.94 each, contributing to a total value of $155,526 for these transactions. Earlier, on March 15, Howe sold shares to cover tax obligations associated with the vesting of performance restricted stock units, resulting in a transaction valued at $128,221 at a price of $44.2143 per share.
These transactions were conducted as part of a Rule 10b5-1 trading plan, allowing insiders to set up a predetermined schedule for buying or selling stock. Following these transactions, Howe maintains direct ownership of 9,436 shares in the company.
In other recent news, Mirum Pharmaceuticals reported fourth-quarter earnings that did not meet analyst expectations, with an adjusted loss of $1.85 per share, compared to the forecasted $0.30 loss per share. However, the company exceeded revenue expectations, posting $99.41 million against the consensus estimate of $95.4 million, marking a 55.6% increase year-over-year. For the full year 2024, Mirum’s net product sales reached $336.4 million, up from $178.9 million in 2023, with LIVMARLI generating $213.3 million and Bile Acid Medicines contributing $123.1 million. Looking ahead, the company has projected 2025 global net product sales between $420 million and $435 million, indicating continued growth. H.C. Wainwright raised its price target for Mirum to $72, maintaining a Buy rating, following the company’s announcement of being on track to meet its 2025 sales guidance. Mirum is also advancing its clinical programs, with the Phase 3 EXPAND study of LIVMARLI and the Phase 2 VISTAS study of volixibat, both progressing toward key milestones. The company aims to achieve positive cash flow in 2025, supported by its expanding product portfolio and recent FDA approvals. Despite the earnings miss, Mirum remains focused on delivering strong financial performance and advancing its clinical pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.